News for Protagonist Therapeutics, Inc. (PTGX)

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell […]

Summary Protagonist Therapeutics Inc (PTGX), a biopharmaceutical company specializing in peptide-based therapeutics, announced on May 21, 2025, that its Preside

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., Presi

Summary Protagonist Therapeutics Inc (PTGX), a biopharmaceutical company specializing in peptide-based therapeutics, announced on May 21, 2025, that its Preside

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]

PR NewswireSPRING HOUSE, Pa., May 9, 2025 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achi

Protagonist Therapeutics (PTGX) has unveiled encouraging findings from its Phase 3 ICONIC-TOTAL study, which explores icotrokinra, an innovative oral peptide ta

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

Protagonist Therapeutics Inc (PTGX) showcases a robust pipeline with advanced clinical programs in inflammatory and immunomodulatory diseases, as well as hemat

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary sess

Protagonist Therapeutics (PTGX) announced a first-quarter revenue of $28.32 million, falling short of the anticipated $30.44 million. Despite this, the company

Summary Protagonist Therapeutics Inc (PTGX) has announced that an abstract detailing the results of their Phase 3 study on Rusfertide for the treatment of polyc

NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for pres

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pion

Protagonist Therapeutics Inc (PTGX) has released new data from its Phase 3 ICONIC-LEAD study, showcasing the efficacy and safety of icotrokinra, an investigatio

PR NewswireSPRING HOUSE, Pa., April 10, 2025 ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess sa

The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Summary Protagonist Therapeutics Inc (PTGX), a clinical-stage biopharmaceutical company specializing in peptide-based therapeutics, has been named to Fast Compa